(Q42199684)

18 October 2017

title

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial (English)

1 reference

multicenter clinical trial

18 October 2017

main subject

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

13

Dieter Häussinger

1 reference

18 October 2017

12

Christian Ohmann

1 reference

18 October 2017

Andreas Erhardt

1

1 reference

18 October 2017

Frank Kolligs

2

1 reference

18 October 2017

Matthias Dollinger

3

1 reference

18 October 2017

Eckart Schott

4

1 reference

18 October 2017

Hennig Wege

5

1 reference

18 October 2017

Michael Bitzer

6

1 reference

18 October 2017

Christiane Gog

7

1 reference

18 October 2017

Frank Lammert

8

1 reference

18 October 2017

Markus Schuchmann

9

1 reference

18 October 2017

Clemens Walter

10

1 reference

18 October 2017

Dirk Blondin

11

1 reference

18 October 2017

publication date

31 August 2014

1 reference

Cancer Chemotherapy and Pharmacology

18 October 2017

published in

1 reference

18 October 2017

volume

74

1 reference

18 October 2017

issue

5

1 reference

18 October 2017

page(s)

947-954

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-014-2568-8

18 October 2017

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Multimodal approaches to the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Vascular actions of anthracycline antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2568-8

10.1007/S00280-014-2568-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

18 October 2017

1009369776

0 references

1 reference